News
Public · Published
Medline Inc. Stock 12‑Month Price Target Raised to $44.62, Implies 31% Upside
Estimates from 26 analysts raised Medline Inc.'s average 12-month stock price target from $44.27 to $44.62. Based on the Nov. 3 closing price, the new target implies approximately 31% potential upside. The consensus rating remains Buy, with 23 Buys, 6 Holds and no Sells among 29 analysts.
Published:
Updated:
What happened
Estimates from 26 analysts raised Medline Inc.’s average 12-month stock price target from $44.27 to $44.62. Based on the Nov. 3 closing price, the new target implies approximately 31% potential upside. The consensus rating remains Buy, with 23 Buys, 6 Holds and no Sells among 29 analysts.
Confirmed
Global impact / market context
A higher analyst target signals that estimates of Medline’s future share value have improved, but it is not a guarantee of returns. If investors act on the implied upside, demand for the stock could rise; the unchanged Buy consensus shows broad optimism, though six analysts remain on Hold.
Analyst inference
The target is an average forecast, not a company promise or a measure of current earnings. Forecasts range from $34 to $55 per share, showing meaningful disagreement among analysts. The article gives no explanation for the revision or information about Medline’s business results.
Confirmed
What to watch
- The next analyst target revisions could show whether the move from $44.27 to $44.62 is followed by further increases or reversed by new estimates. Analyst inference
- Compare future company results with the $34-to-$55 forecast range; results that differ from analysts’ expectations could change their targets and ratings. Analyst inference
- The consensus remains Buy, with 23 Buys, 6 Holds and no Sells among 29 analysts; watch whether that rating mix changes in later updates. Confirmed
Evidence
- Original source link unavailable